Thursday, March 25, 2021 8:37:07 AM
Fugitive447
Bullish
3/24/21, 09:47 PM
AUPH
This is getting depressing. To cure myself I listened in once again to Dr James Tumblin who was the guest speaker tonight as part of the Attend the speaker series: Introduction to LUPKYNIS.
Couple highlights
He sees Lupkynis as an easy to administer maintenance medication. He strongly believes that Lupkynis is less nephrotoxic than other CNIs paving the way to replace those medications in other indications. Test are now in process to attempt to validate that. He took many questions from other nephrologist's and rheumatologists . One question concerned Lupkynis being used for other indications. He emphatically stated yes and those diseases would be GN disease related or Glomerulonephritis one such disease is FSGS there are others. He personally believed Lupkynis could play a role in diabetes treatment!
He took a question about MMF and Benlysta. He commented he was always concerned with the trial results and the fact after 6 months Benlysta flat lined on protenuria reduction.
Recent AUPH News
- Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 • Business Wire • 06/05/2024 10:00:00 AM
- Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce • Business Wire • 06/04/2024 09:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/04/2024 09:25:39 PM
- Aurinia Provides Update on Proxy Statement • Business Wire • 06/03/2024 10:30:00 PM
- Aurinia Will Attend 2024 Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:11:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:07:15 PM
- Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 • Business Wire • 05/14/2024 10:00:00 AM
- Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 • Business Wire • 05/09/2024 10:00:00 AM
- Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 10:00:00 AM
- Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results • Business Wire • 05/02/2024 10:00:00 AM
- Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month • Business Wire • 05/01/2024 10:00:00 AM
- The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program • Business Wire • 04/30/2024 10:00:00 AM
- New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/16/2024 02:48:00 PM
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 • Business Wire • 04/15/2024 10:00:00 AM
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference • Business Wire • 04/09/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:44:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:43:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:42:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:41:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:10:10 PM
- Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program • Business Wire • 02/29/2024 01:30:00 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM